Does Rallies track congressional trades in SLDB?

Yes. Rallies tracks politician and congressional stock disclosures for SLDB, including reported purchases, sales, dates, owners, and trade amounts when available.

Is SLDB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SLDB. It does not provide personalized investment advice.

SLDB (Solid Biosciences Inc. Common Stock) Stock Analysis - Politician Trades

Solid Biosciences Inc. Common Stock (SLDB) is a publicly traded Healthcare sector company. As of May 20, 2026, SLDB trades at $6.47 with a market cap of $640.91M and a P/E ratio of -3.19. SLDB moved +6.58% today. Year to date, SLDB is +21.39%; over the trailing twelve months it is +119.32%. Its 52-week range spans $2.41 to $8.87. Analyst consensus is strong buy with an average price target of $17.33. Rallies surfaces SLDB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded SLDB stock?

Rallies tracks politician and congressional stock disclosures for SLDB, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

SLDB Key Metrics

Key financial metrics for SLDB
Metric	Value
Price	$6.47
Market Cap	$640.91M
P/E Ratio	-3.19
EPS	$-1.99
Dividend Yield	0.00%
52-Week High	$8.87
52-Week Low	$2.41
Volume	974.73K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-174.32M
Gross Margin	0.00%

Latest SLDB News

Solid Biosciences Doses First Phase 3 Duchenne Participant, Holds $380.7M Cash Runway — May 12, 2026
Solid Biosciences Secures $240M Funding, Targets April Phase 3 Duchenne Dosing — Mar 19, 2026
Solid Biosciences Achieves 91% Microdystrophin Expression, 44% eMHC Reduction in Trial — Mar 11, 2026
Solid Biosciences Shares Jump 12% on Gene Therapy Approval Tailwind — Mar 9, 2026
FDA Grants Orphan Drug Status to Solid Biosciences’ SGT-212 and Doses First FALCON Patient — Jan 14, 2026

Recent SLDB Insider Trades

Cumbo Alexander sold 16.64K (~$96.92K) on Feb 18, 2026.
Hanrahan Jessie sold 4.13K (~$24.07K) on Feb 18, 2026.
Ganot Ilan sold 2.66K (~$15.48K) on Feb 18, 2026.

SLDB Analyst Consensus

11 analysts cover SLDB: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.33.

Common questions about SLDB

Which politicians traded SLDB stock?: Rallies tracks politician and congressional stock disclosures for SLDB, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in SLDB?: Yes. Rallies tracks politician and congressional stock disclosures for SLDB, including reported purchases, sales, dates, owners, and trade amounts when available.
Is SLDB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SLDB. It does not provide personalized investment advice.